ARTICLE | Clinical News

IDEC-CE9 data

June 27, 1994 7:00 AM UTC

IDPH (San Diego) reported Phase I results in 25 patients, showing reduction of arthritic symptoms in 13, with no adverse reactions or immune rejection.

A single infusion of the antibody was tested, with doses ranging from 0.03 to 4.0 mg/kg, using the Richie index of symptoms. The patients underwent a washout period before the agent was given. ...